BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  Caidya Announces Leadership Transition: Barbara Lopez Kunz Named CEO

  July 22, 2024

   · 

  3 min read
• Press Releases

  Revision Skincare® to Host its Annual Business-Building Elite Retreat for Top Aesthetics Practices Across the U.S., Showcasing Trailblazing Women Who Make an Impact

  July 22, 2024

   · 

  3 min read
• 

  Press Releases

  B-Cell Non-Hodgkin Lymphoma Market to Reach a CAGR of 5.83% during 2024-2034, Impelled by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

  July 22, 2024

   · 

  11 min read
• 

  Press Releases

  Chronic Hepatitis B Market to Reach USD 3,379.3 Million by 2034, Impelled by Immune Modulation Strategies

  July 22, 2024

   · 

  11 min read
• 

  Diabetes

  Innovent’s Lilly-Partnered Type 2 Diabetes Drug Aces Phase III in China, Inches Closer to Approval

  Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.

  July 22, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Press Releases

  Helicobacter Pylori Market to Reach USD 3,891.7 Million by 2034, Impelled by Polymerase Chain Reaction Technique

  July 22, 2024

   · 

  10 min read
• 

  Press Releases

  Hernia Market to Reach a CAGR of 2.28% during 2024-2034, Impelled by Increased Demand for Robot-Assisted Surgery

  July 22, 2024

   · 

  10 min read
• 

  Press Releases

  Human Papillomavirus Market to Reach a CAGR of 8.33% during 2024-2034, Impelled by the Emerging Popularity of Cryotherapy

  July 22, 2024

   · 

  11 min read
• 

  FDA

  Samsung Bioepis Gets FDA Approval for Biosimilar to AstraZeneca’s Soliris

  The South Korean company’s Epysqli is now FDA-approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in the U.S., having grabbed the lead in the Soliris biosimilar market in Europe.

  July 22, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• Press Releases

  Wake Radiology UNC Rex Healthcare’s Advanced Screening Bone Density Scan Technology Provides New Early-Warning Information to Patients About Osteoporosis Risk

  July 22, 2024

   · 

  2 min read